HONOKIOL

Possibly Marketed Outside US

First approved in 2021

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H18O2
Molecular Weight	266.3343
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=C(O)C=C2

InChI

InChIKey=FVYXIJYOAGAUQK-UHFFFAOYSA-N

InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2

HIDE SMILES / InChI

Molecular Formula	C18H18O2
Molecular Weight	266.3343
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27671820 | https://www.ncbi.nlm.nih.gov/pubmed/28817221 | http://adisinsight.springer.com/drugs/800042917

Honokiol is a biphenolic natural product isolated from the bark and leaves of Magnolia plant spp. Honokiol possesses anti-carcinogenic, anti-inflammatory, anti-oxidative, anti-angiogenic as well as the inhibitory effect on malignant transformation of papillomas to carcinomas in vitro and in vivo animal models without any appreciable toxicity. Honokiol affects multiple signaling pathways, molecular and cellular targets including nuclear factor-κB (NF-κB), STAT3, epidermal growth factor receptor (EGFR), cell survival signaling, cell cycle, cyclooxygenase and other inflammatory mediators, etc. Honokiol can permeate the blood-brain barrier and the blood-cerebrospinal fluid to increase its bioavailability in neurological tissues. Diverse studies have provided evidence on the neuroprotective effect of honokiol in the central nervous system, due to its potent antioxidant activity, and amelioration of the excitotoxicity mainly related to the blockade of glutamate receptors and reduction in neuroinflammation. Honokiol can attenuate neurotoxicity exerted by abnormally aggregated Abeta in Alzheimer's disease. Honokiol is being developed by Huons as HL tablet for the treatment of alcoholic and non-alcoholic fatty liver.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NF-kappa B signaling pathway 87 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28848085	Inhibitor 8504
STAT3 signaling pathway 2 Target ID: STAT3 signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/27849557	Inhibitor 8504
autophagy 17 Target ID: GO:0006914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27236003 \| https://www.ncbi.nlm.nih.gov/pubmed/27774504	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Non-alcoholic fatty liver disease 32 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28932090 http://adisinsight.springer.com/drugs/800042917	Primary	Phase II 1147	Unknown Approved Use Unknown
Alzheimer’s disease 278 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28848085 https://www.ncbi.nlm.nih.gov/pubmed/28817221	Primary	Preclinical	Unknown Approved Use Unknown
Lung cancer 70 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27849557	Primary	Preclinical	Unknown Approved Use Unknown
Glioma 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27236003 https://www.ncbi.nlm.nih.gov/pubmed/27774504	Primary	Preclinical	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inducer 440 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 UGT1A1 246 UGT1A9 148 CYP2A6 879 CYP2B6 926 CYP2C19 2057 UGT1A4 98 UGT2B7 197 UGT1A8 37 BCRP 910 SULT1E1 5 P-gp 1741 SULT1A1 4 UGT1A10 37 SULT1A2 1	SULT1A1 37 UGT1A10 331 SULT1A2 3 UGT1A1 479 UGT2B4 278 UGT1A3 470 UGT1A6 343 SULT1C4 3 SULT1B1 8 UGT2B7 456 UGT1A8 323 SULT1E1 22 UGT1A9 423 SULT2A1 28 UGT2B15 236 UGT1A4 399 SULT1A3 31 SULT1C2 3 UGT2B17 237 UGT1A7 249	CYP2C19 329 UGT1A1 78 CYP2B6 669 CYP2C8 198 CYP1A2 832 UGT1A4 5 UGT1A9 9 UGT2B7 14 SULT2A1 4

Drug as perpetrator

Target	Modality	Activity
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	moderate [IC50 13.8 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	moderate [IC50 14 uM]
SULT1A1 8	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	moderate [Ki 32.6 uM]
UGT1A4 100	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no [IC50 158.1 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no [IC50 97.3 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1325#sid=24823977	no
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	no
CYP2C19 2141	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2C8 1117	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP2C9 2497	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
CYP3A4 2633	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
SULT2A1 9	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A1 303	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A4 100	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A9 155	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT2B7 210	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	no
UGT1A10 46	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 1392 uM]
UGT1A8 49	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 1709 uM]
SULT1E1 5	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	unlikely [Ki 262 uM]
UGT2B7 210	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	weak [IC50 36.4 uM]
UGT1A1 303	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	weak [IC50 50.5 uM]
SULT1A2 1	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	weak [Ki 79.8 uM]
CYP2B6 1160	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/25395831/	weak
UGT1A9 155	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 0.96 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 2.1 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 2.2 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 4.1 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24005963/	yes [IC50 8.9 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26454249/	yes
P-gp 1932	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/23060571/	yes

Drug as victim

Target	Modality	Activity
SULT1B1 8	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely [Km 0.41 uM]
SULT1C4 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	likely
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	major [Km 1.32 uM]
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	major [Km 3.67 uM]
SULT1E1 22	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor [Km 0.85 uM]
SULT1A3 31	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/	minor [Km 1.07 uM]
UGT2B17 237	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	minor
SULT1C2 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	no
SULT2A1 28	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	no
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 0.84 uM]
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 1.82 uM]
SULT1A1 37	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 48 uM]
SULT1A2 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21404278/ \| https://pubmed.ncbi.nlm.nih.gov/26983827/	yes [Km 92.3 uM]
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26983827/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/720551#sid=49681541

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003A2V	https://www.1pchem.com/search?query=1P003A2V
A2B Chem	AB52231	http://a2bchem.com/prod/AB52231
AA Blocks	AA0039JF	http://aablocks.com/goods/Goods/detail?id=AA0039JF
AK Scientific	J10347	https://aksci.com/item_detail.php?cat=J10347
AK Scientific	O900	https://aksci.com/item_detail.php?cat=O900
Ambeed	A146214	http://www.ambeed.com/search/Search.html?keyword=A146214
ApexBio Technology	N1672	https://www.apexbt.com/catalogsearch/result/?q=N1672
AstaTech	44247	http://astatechinc.com/CPSResult.php?CRNO=44247
Biopurify Phytochemicals	BP0736	https://www.phytopurify.com/search.do?a=s&searchtype=3&psize=10&q=BP0736&searchhtmp=simplesearch&t=1
BioSynth	Q-100425	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100425
BOC Sciences	35354-74-6	http://www.bocsci.com/description.asp?cas=35354-74-6
Cayman Chemical	14597	http://www.caymanchem.com/app/template/Product.vm/catalog/14597
Chem Scene	CS-1696	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1696
Chem4Pharma	C4PN24	https://www.chem4pharma.com/product-page/C4PN24
ChemShuttle	141534	https://www.chemshuttle.com/catalogsearch/result/?q=141534
Combi-Blocks	QB-3220	http://www.combi-blocks.com/cgi-bin/find.cgi?QB-3220
eMolecules	539203	https://orderbb.emolecules.com/search/#?query=539203
eNovation Chemicals	D401651	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D401651&searchbtn.x=0&searchbtn.y=0
Fluorochem	221573	http://www.fluorochem.co.uk/Products/Product?code=221573
Hairui	HOJB001	http://www.hairuichem.com/en/product/search.do?q=HOJB001
KeyOrganics	AS-15333	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-15333
Lab Network	LN00222478	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00222478
Lab Seeker	SC-17371	http://www.labseeker.com/search.php?keywords=SC-17371&category=0
LabSeeker	SC-17371	http://www.labseeker.com/search.php?keywords=SC-17371&category=0
mcule	MCULE-5001549020	https://mcule.com/MCULE-5001549020/
MedChem Express	HY-N0003	https://www.medchemexpress.com/search.html?q=HY-N0003&ft=&fa=&fp=
Molnova	M14205	https://www.molnova.com/en/serch-list.html?keywords=M14205
MolPort	MolPort-002-507-432	https://www.molport.com/shop/molecule-link/MolPort-002-507-432
MuseChem	I003289	https://www.musechem.com/product/I003289.html
PI Chemicals	PI-28431	http://www.pipharm.com/catalog_products/PI-28431.html
Ryan Scientific	Magnolol	https://ryansci.com/products?q=Magnolol&list_q=&search_type=exact
Selleck Chemicals	S2310	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2310
ShangHai Biochempartner	BCP28282	http://www.biochempartner.com/search_BCP28282
TargetMol	BBP02794	https://www.targetmol.com/search?keyword=BBP02794
TargetMol	T3001	https://www.targetmol.com/search?keyword=T3001
Tetrahedron	TS08538	http://www.thsci.com/search.do?q=TS08538
Tocris	4590	https://www.tocris.com/search.php?Type=QuickSearch&Value=4590
Toronto Research Chemicals	E950000	https://www.trc-canada.com/product-detail/?CatNum=E950000
Toronto Research Chemicals	H669560	https://www.trc-canada.com/product-detail/?CatNum=H669560
Vesino Industrial Co Ltd	VZ32385	http://www.vsnchem.com/search.do?a=s&psize=20&q=VZ32385
Vitas-M Laboratory	BBL027819	http://www.vitasmlab.biz/search/BBL027819
Vitas-M Laboratory	STK801954	http://www.vitasmlab.biz/search/STK801954
W&J PharmaChem	50C114705	http://wjpharmachem.com/new/searcht.php?keyword=50C114705

PubMed

Title	Date	PubMed
Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.	2008-09	18350317
Rapid simultaneous quantification of five active constituents in rat plasma by high-performance liquid chromatography/tandem mass spectrometry after oral administration of Da-Cheng-Qi decoction.	2008-07-15	18358661
Preparation and characterization of honokiol nanoparticles.	2008-07	18197366
Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes.	2008-06	18369342
Differential proteomic analysis of HeLa cells treated with Honokiol using a quantitative proteomic strategy.	2008-06	18157584
Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents.	2008-04-01	18093712
Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB.	2008-03-17	18241858
Chlorogenic acid and its metabolite m-coumaric acid evoke neurite outgrowth in hippocampal neuronal cells.	2008-03	18323641
Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo.	2008-03	17914455
Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.	2008-02-15	18281560
Preparative purification of anti-tumor derivatives of honokiol by high-speed counter-current chromatography.	2008-01-18	18082756
Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression.	2008-01	18158873
Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract.	2007-12	17692444
Compressed mints and chewing gum containing magnolia bark extract are effective against bacteria responsible for oral malodor.	2007-11-14	17949053
Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors.	2007-11	17978501
Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth.	2007-10-31	17971859
Liquid chromatographic determination of honokiol and magnolol in hou po (Magnolia officinalis) as the raw herb and dried aqueous extract.	2007-10-25	17955964
Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line.	2007-10-02	17908330
Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.	2007-10	17938262
Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA.	2007-10	17470388
Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.	2007-09-26	17892458
Effects of honokiol and magnolol on acute and inflammatory pain models in mice.	2007-09-08	17826802
Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol.	2007-08-15	17587572
Honokiol, a neuroprotectant against mouse cerebral ischaemia, mediated by preserving Na+, K+-ATPase activity and mitochondrial functions.	2007-08	17651312
Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis.	2007-07-15	17617564
Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS.	2007-06-15	17400527
[Effects of the active compounds of M. officinalis on cariogenic bacteria].	2007-06	17593830
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.	2007-06	17487375
Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore.	2007-05-15	17510419
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.	2007-04-01	17326044
Analysis of magnolol and honokiol in biological fluids by capillary zone electrophoresis.	2007-02-23	17234199
Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography.	2007-02-23	17222860
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells.	2007-01-18	17233906
Honokiol up-regulates prostacyclin synthease protein expression and inhibits endothelial cell apoptosis.	2007-01-05	17109844
[Investigate into of effective constituent transference of herba Ephedrae and cortex Magnoliae officinalis in preparation course of Shujin Kechuan capsule].	2006-12	17348186
Determination of liquiritin, naringin, hesperidin, thymol, imperatorin, honokiol, isoimperatorin, and magnolol in the traditional Chinese medicinal preparation Huoxiang-zhengqi liquid using high-performance liquid chromatography.	2006-11	17077620
Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.	2006-10-02	16962592
[Optimization of preparative technique for banxia-houpu effervescent tablets by orthogonal design].	2006-10	17326411
[Evaluation of antioxidant activity of Radix Linderae and other two Chinese drugs using TLC-bioautography].	2006-10	17184113
Simultaneous determination of honokiol and magnolol in Magnolia officinalis by liquid chromatography with tandem mass spectrometric detection.	2006-10	16583454
Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway.	2006-09	16966432
Ethnoveterinary medicines used for horses in Trinidad and in British Columbia, Canada.	2006-08-07	16893454
Carbon nanotube/poly(methyl methacrylate) composite electrode for capillary electrophoretic measurement of honokiol and magnolol in Cortex Magnoliae Officinalis.	2006-08	16850507
Honokiol, a small molecular weight natural product, alleviates experimental mesangial proliferative glomerulonephritis.	2006-08	16807544
Determination of honokiol and magnolol in cortex Magnoliae Officinalis by capillary electrophoresis with electrochemical detection.	2006-06-16	16704915
Facile purification of honokiol and its antiviral and cytotoxic properties.	2006-06-01	16722664
Honokiol reduces oxidative stress, c-jun-NH2-terminal kinase phosphorylation and protects against glycochenodeoxycholic acid-induced apoptosis in primary cultured rat hepatocytes.	2006-06	16732532
Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage.	2006-05-10	16631734
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.	2006-02	17576437
Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis.	2004-03	17191867

Patents

Sample Use Guides

In Vivo Use Guide

High dose 400 mg and low dose 133.4 mg daily for 12 weeks

Route of Administration: Oral

In Vitro Use Guide

Honokiol inhibited the proliferation of both glioblastoma multiforme (GBM8401) parental cells and cancer stem-like side population (SP) cells in a dose-dependent manner, the IC50 were 5.3 and 11 uM, respectively. The proportions of cancer stem-like side population (SP) in GBM8401 cells were diminished by Honokiol from 1.5 % down to 0.3 % and 0.2 % at doses of 2.5 uM and 5 uM, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:02:53 GMT 2025` Edited by `admin` on `Mon Mar 31 21:02:53 GMT 2025`
Record UNII	11513CCO0N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HONOKIOL

Official Name

English

FMLT BSASM H

Preferred Name

English

HONOKIOL [MI]

Common Name

English

(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPEN-1-YL-

Systematic Name

English

3',5-DIALLYL-2,4'-BIPHENYLDIOL

Systematic Name

English

NSC-293100

Code

English

PURINOL

Systematic Name

English

(1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPENYL-

Systematic Name

English

Honokiol [WHO-DD]

Common Name

English

Classification Tree Code System Code

DSLD

2680 (Number of products:8)